STONE BENJAMIN 4

What Happened Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics (TRAX), received equity awards on May 12, 2026: 26,700 restricted stock units (RSUs) and an option grant covering 72,300 shares. Both awards were reported as acquired at $0.00 (no cash exchanged) and are derivative awards (not open-market purchases or sales). The RSUs are rights to receive shares upon settlement; the option grant gives the right to purchase shares subject to vesting.

Key Details

• Transaction date: May 12, 2026. Form filed May 14, 2026 (timely filing).
• Awards: 26,700 RSUs and an option grant for 72,300 shares; reported price $0.00; reported immediate value $0 (award/grant).
• Vesting (per footnotes): RSUs vest 25% annually beginning May 12, 2027. The option vests 25% on May 12, 2027, then 1/48 of the total monthly thereafter until fully vested.
• Additional holdings: Reporting person also holds options to purchase up to an aggregate 337,140 additional shares (vests per separate terms).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding sale, or immediate sale of shares in this filing.

Context RSUs are contingent rights to receive shares upon settlement and do not require immediate cash outlay; option grants give a future right to buy shares according to the vesting schedule. Grants are common executive compensation and do not, by themselves, indicate immediate buying or selling intent. This filing documents compensation-related awards rather than open-market insider purchases or dispositions.